Skip to main content
Top
Published in: Strahlentherapie und Onkologie 4/2017

01-04-2017 | Original Article

Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?

A planning study

Authors: A. Botticella, MD, G. Defraene, K. Nackaerts, C. Deroose, J. Coolen, P. Nafteux, B. Vanstraelen, S. Joosten, L. A. W. Michiels, S. Peeters, D. De Ruysscher

Published in: Strahlentherapie und Onkologie | Issue 4/2017

Login to get access

Abstract

Background

After lung-sparing radiotherapy for malignant pleural mesothelioma (MPM), local failure at sites of previous gross disease represents the dominant form of failure. Our aim is to investigate if selective irradiation of the gross pleural disease only can allow dose escalation.

Materials and methods

In all, 12 consecutive stage I–IV MPM patients (6 left-sided and 6 right-sided) were retrospectively identified and included. A magnetic resonance imaging-based pleural gross tumor volume (GTV) was contoured. Two sets of planning target volumes (PTV) were generated for each patient: (1) a “selective” PTV (S-PTV), originating from a 5-mm isotropic expansion from the GTV and (2) an “elective” PTV (E-PTV), originating from a 5-mm isotropic expansion from the whole ipsilateral pleural space. Two sets of volumetric modulated arc therapy (VMAT) treatment plans were generated: a “selective” pleural irradiation plan (SPI plan) and an “elective” pleural irradiation plan (EPI plan, planned with a simultaneous integrated boost technique [SIB]).

Results

In the SPI plans, the average median dose to the S‑PTV was 53.6 Gy (range 41–63.6 Gy). In 4 of 12 patients, it was possible to escalate the dose to the S‑PTV to >58 Gy. In the EPI plans, the average median doses to the E‑PTV and to the S‑PTV were 48.6 Gy (range 38.5–58.7) and 49 Gy (range 38.6–59.5 Gy), respectively. No significant dose escalation was achievable.

Conclusion

The omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, Guidelines Committee ESMO (2015) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(S5):v31–v39CrossRefPubMed Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, Guidelines Committee ESMO (2015) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(S5):v31–v39CrossRefPubMed
2.
go back to reference Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889CrossRefPubMed Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889CrossRefPubMed
3.
go back to reference Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644CrossRefPubMed
4.
go back to reference Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, European Respiratory Society, European Society of Thoracic Surgeons Task Force et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35:479–495CrossRefPubMed Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, European Respiratory Society, European Society of Thoracic Surgeons Task Force et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35:479–495CrossRefPubMed
5.
go back to reference Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD et al (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–245CrossRefPubMed Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD et al (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–245CrossRefPubMed
6.
go back to reference Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB et al (2014) Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 9:390–396CrossRefPubMed Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB et al (2014) Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 9:390–396CrossRefPubMed
7.
go back to reference Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41:503–510 (Jun)CrossRefPubMedPubMedCentral Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41:503–510 (Jun)CrossRefPubMedPubMedCentral
8.
go back to reference Marcq E, Pauwels P, van Meerbeeck JP, Smits EL (2015) Targeting immune checkpoints: New opportunity for mesothelioma treatment? Cancer Treat Rev 41:914–924CrossRefPubMed Marcq E, Pauwels P, van Meerbeeck JP, Smits EL (2015) Targeting immune checkpoints: New opportunity for mesothelioma treatment? Cancer Treat Rev 41:914–924CrossRefPubMed
9.
10.
go back to reference Minatel E, Trovo M, Polesel J, Rumeileh IA, Baresic T, Bearz A et al (2012) Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. J Thorac Oncol 7:1862–1866CrossRefPubMed Minatel E, Trovo M, Polesel J, Rumeileh IA, Baresic T, Bearz A et al (2012) Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. J Thorac Oncol 7:1862–1866CrossRefPubMed
11.
go back to reference Minatel E, Trovo M, Polesel J, Baresic T, Bearz A, Franchin G et al (2014) Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer 83:78–82CrossRefPubMed Minatel E, Trovo M, Polesel J, Baresic T, Bearz A, Franchin G et al (2014) Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer 83:78–82CrossRefPubMed
12.
go back to reference Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS et al (2012) Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 83:1278–1283CrossRefPubMedPubMedCentral Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS et al (2012) Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 83:1278–1283CrossRefPubMedPubMedCentral
13.
go back to reference Fodor A, Fiorino C, Dell’Oca I, Broggi S, Pasetti M, Cattaneo GM et al (2011) PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol 187:736–743CrossRefPubMed Fodor A, Fiorino C, Dell’Oca I, Broggi S, Pasetti M, Cattaneo GM et al (2011) PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol 187:736–743CrossRefPubMed
14.
go back to reference Feigen M, Lee ST, Lawford C, Churcher K, Zupan E, Scott AM et al (2011) Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F‑FDG PET/CT scan correlation. J Med Imaging Radiat Oncol 55:320–332CrossRefPubMed Feigen M, Lee ST, Lawford C, Churcher K, Zupan E, Scott AM et al (2011) Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F‑FDG PET/CT scan correlation. J Med Imaging Radiat Oncol 55:320–332CrossRefPubMed
15.
go back to reference Rimner A, Spratt DE, Zauderer MG, Rosenzweig KE, Wu AJ, Foster A et al (2014) Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 90:394–401CrossRefPubMed Rimner A, Spratt DE, Zauderer MG, Rosenzweig KE, Wu AJ, Foster A et al (2014) Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 90:394–401CrossRefPubMed
16.
go back to reference Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z et al (2015) Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91:149–156CrossRefPubMed Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z et al (2015) Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91:149–156CrossRefPubMed
17.
go back to reference Minatel E, Trovo M, Bearz A, Di Maso M, Baresic T, Drigo A et al (2015) Radical radiation therapy after lung-sparing surgery for malignant pleural Mesothelioma: Survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys 93:606–613CrossRefPubMed Minatel E, Trovo M, Bearz A, Di Maso M, Baresic T, Drigo A et al (2015) Radical radiation therapy after lung-sparing surgery for malignant pleural Mesothelioma: Survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys 93:606–613CrossRefPubMed
18.
go back to reference Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRefPubMed Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRefPubMed
19.
go back to reference Botticella A, Defraene G, Nackaerts K, Deroose CM, Coolen J, Nafteux P, Peeters S, De Ruysscher D (2015) Optimization of gross tumor volume definition and treatment planning in lung-sparing volumetric modulated arc therapy for pleural mesothelioma. Ann Oncol 26(Supplement 1):i48–i50CrossRef Botticella A, Defraene G, Nackaerts K, Deroose CM, Coolen J, Nafteux P, Peeters S, De Ruysscher D (2015) Optimization of gross tumor volume definition and treatment planning in lung-sparing volumetric modulated arc therapy for pleural mesothelioma. Ann Oncol 26(Supplement 1):i48–i50CrossRef
20.
go back to reference Botticella A, Defraene G, Nackaerts K, Deroose CM, Coolen J, Nafteux P et al (2016) Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: An in silico study. Acta Oncol 55:1450–1455CrossRefPubMed Botticella A, Defraene G, Nackaerts K, Deroose CM, Coolen J, Nafteux P et al (2016) Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: An in silico study. Acta Oncol 55:1450–1455CrossRefPubMed
21.
go back to reference Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM et al (2010) Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:77–85CrossRef Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM et al (2010) Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:77–85CrossRef
22.
go back to reference Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR et al (2006) Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65:640–645CrossRefPubMed Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR et al (2006) Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65:640–645CrossRefPubMed
23.
go back to reference Brock KK, Dawson LA (2014) Point: Principles of magnetic resonance imaging integration in a computed tomography-based radiotherapy workflow. Semin Radiat Oncol 24:169–174CrossRefPubMed Brock KK, Dawson LA (2014) Point: Principles of magnetic resonance imaging integration in a computed tomography-based radiotherapy workflow. Semin Radiat Oncol 24:169–174CrossRefPubMed
24.
go back to reference Krayenbuehl J, Hartmann M, Lomax AJ, Kloeck S, Hug EB, Ciernik IF (2010) Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. Int J Radiat Oncol Biol Phys 78:628–634CrossRefPubMed Krayenbuehl J, Hartmann M, Lomax AJ, Kloeck S, Hug EB, Ciernik IF (2010) Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. Int J Radiat Oncol Biol Phys 78:628–634CrossRefPubMed
Metadata
Title
Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?
A planning study
Authors
A. Botticella, MD
G. Defraene
K. Nackaerts
C. Deroose
J. Coolen
P. Nafteux
B. Vanstraelen
S. Joosten
L. A. W. Michiels
S. Peeters
D. De Ruysscher
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 4/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1108-y

Other articles of this Issue 4/2017

Strahlentherapie und Onkologie 4/2017 Go to the issue